Acumen Pharmaceuticals' Board of Directors announced the appointment of Jeffrey Ives, Ph.D., to the company's Board of Directors. Dr. Ives's scientific leadership experience and expertise in drug development for Alzheimer's disease will support Acumen's advancement as its lead drug candidate, ACU-193, a novel, first in class, humanized monoclonal antibody that selectively targets soluble amyloid-beta oligomers, which are widely recognized as a key toxin causing Alzheimer's disease. Dr. Ives is a Principal for NeuroPharma Advisors, LLC.